Happy Holidays from Omixon!

22/12/2017

From all of us at Omixon, we wish to all our friends, partners and everyone else we met during the last couple of years a very happy holiday season with our first Omixon Holiday Song – without you, this year would not have been this eventful and exciting. Happy Ho-Ho-Holotyping!...

The Year in Blog Posts – Favourite Announcements from 2017

19/12/2017

As the year ends, we think about all we are grateful for. It has indeed been a pleasure working with you throughout this year and we believe that our amazing sequel will continue. From events to product releases, from new hires to an impressive distributor network we’ve done well! We launched...

How Immunotherapy of Cancer May Create Novel Clinical Utilities for HLA Typing

15/12/2017

Written by Dr. Attila Bérces (Founder and Chairman, Omixon) The article was originally published in ASHI Quarterly Q3 2017 While the role of HLA has been demonstrated in over hundred diseases, its clinical utility and impact outside transplantation has been limited. Transplantation still dominates the demand for HLA genotyping....

Continued Innovation – Holotype HLA V2.2

30/11/2017

Omixon is delighted to announce the latest evolution of our world-leading HLA Typing product – Holotype HLA V2.1 and V2.2. Both versions deliver improved amplification robustness, increased allele coverage across Class II loci and decreased the library preparation turnaround time to ~4.3h. The major difference between V2.1 and V2.2 is...

Celebrate Our Corporate Growth!

29/11/2017

Since being founded as a software company in 2011, Omixon has evolved in numerous ways, including a pivot in 2014 to become a burgeoning global molecular diagnostics company with expertise in HLA, immunogenetics, software development, bioinformatics & genomics across all divisions in the company. As we push on towards winter...